Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has demonstrated promising developments in its clinical pipeline, notably with positive top-line results reported in June 2023, which enhance the potential for its therapeutic candidates targeting neurodegenerative diseases and psychiatric disorders. The company's innovative approach, utilizing patented technologies for lithium delivery and immunological restoration, positions it uniquely in the biopharmaceutical market, addressing critical unmet needs in Alzheimer's treatment. Furthermore, the company's current valuation is deemed attractive, suggesting that achieving upcoming milestones and positive trial data could serve as significant catalysts for future stock performance.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeded the analysts' estimates of $(0.69). The company faces substantial risks including liquidity issues, the potential failure of its drug candidates to show safety and efficacy in trials, and challenges in gaining regulatory approvals, all of which could impede its business prospects. Additionally, external factors such as competition and shifting investor sentiment towards biotech stocks further contribute to concerns regarding the company's future performance.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.